GLOBE,
IOL,
Marketing,
Investment,
Risk,
U.S. Securities and Exchange Commission,
Technology,
Sale,
LAL,
Visual acuity,
SEC,
Company,
Terminology,
Patient,
Growth,
Security (finance),
LDD,
Video game,
Risk management,
Part Two In the third quarter of 2022, total revenue was $12.6 million, an increase of 118% compared to the third quarter of 2021.
Key Points:
- In the third quarter of 2022, total revenue was $12.6 million, an increase of 118% compared to the third quarter of 2021.
- Total operating expenses for the third quarter of 2022 were $21.3 million, a 47.5% increase from $14.5 million in the third quarter of 2021.
- Based on its third quarter 2022 performance, RxSight has revised its 2022 full-year revenue guidance to a range of $47.0 million to $48.0 million, compared to prior guidance of $44.0 million to $46.0 million.
- On Monday, November 7, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time, the company will host a conference call to discuss its third quarter 2022 financial results.
ALISO VIEJO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the third quarter 2022 after the market close on Monday, November 7, 2022.
Key Points:
- ALISO VIEJO, Calif., Oct. 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the third quarter 2022 after the market close on Monday, November 7, 2022.
- The companys management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- Participants may register for the call here and listen through a live and archived webcast of the event available for one year at https://investors.rxsight.com/ .
- RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery.
Retrieved on:
Wednesday, August 24, 2022
ALISO VIEJO, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced plans to participate in the upcoming Wells Fargo Healthcare Conference.
Key Points:
- ALISO VIEJO, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced plans to participate in the upcoming Wells Fargo Healthcare Conference.
- RxSights management is scheduled to participate in a fireside chat Thursday, September 8, 2022, at 8:35 a.m. Pacific Time / 11:35 a.m. Eastern Time.
- Interested parties may access a live and archived webcast of the presentation at: https://investors.rxsight.com/ .
- RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery.
U.S. Securities and Exchange Commission,
GLOBE,
Form,
Technology,
Private Securities Litigation Reform Act,
SEC,
Visual acuity,
Terminology,
Sale,
Prospectus,
ATM,
Security (finance),
Form S-3,
EDGAR,
Patient,
Company,
LAL,
Attention,
BofA Securities,
NASDAQ,
Share (finance),
IOL,
3rd Floor,
Time The shelf registration statement is intended to provide the Company with flexibility to access additional capital when market conditions are appropriate.
Key Points:
- The shelf registration statement is intended to provide the Company with flexibility to access additional capital when market conditions are appropriate.
- As part of the shelf registration, the Company also filed a prospectus supplement to sell, of the $200 million of securities being registered, up to an aggregate of $50 million of its common stock (the "Shares") through an "at-the-market" ("ATM") offering.
- The registration statement has been filed with the SEC, but has not yet become effective.
- These securities may not be sold, nor may offers to buy be accepted prior to the time that the registration statement becomes effective.
GLOBE,
Technology,
Investment,
Visual acuity,
Sale,
Marketing,
Patient,
LAL,
Company,
NASDAQ,
Â,
LDD,
IOL,
Terminology,
Video game,
Pharmaceutical industry,
Aquaculture Delivered second quarter 2022 revenue of $11.4 million, an increase of 132% compared to the second quarter of 2021, reflecting:
Key Points:
- Delivered second quarter 2022 revenue of $11.4 million, an increase of 132% compared to the second quarter of 2021, reflecting:
The sale of 49 Light Delivery Devices (LDDs), representing a 96% unit increase from the second quarter of 2021, expanding the installed base to 294 LDDs at the end of the quarter, a 126% increase compared to the 130-unit LDD installed base at the end of the second quarter of 2021.
- In the second quarter of 2022, total revenue was $11.4 million, an increase of 132% compared to the second quarter of 2021.
- Total operating expenses for the second quarter of 2022 were $20.6 million, a 57.5% increase from $13.1 million in the second quarter of 2021.
- On Monday, August 8, 2022, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its second quarter 2022 financial results.
ALISO VIEJO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the second quarter 2022 after the market close on Monday, August 8, 2022.
Key Points:
- ALISO VIEJO, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the second quarter 2022 after the market close on Monday, August 8, 2022.
- The companys management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- Instructions are provided (including a dial-in option) to ensure the necessary audio applications are downloaded and installed.
- RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery.
Investment,
LAL,
NASDAQ,
GLOBE,
Patient,
International,
Marketing,
Sale,
Visual acuity,
Terminology,
LDD,
Technology,
IOL,
Health insurance,
Video game Revised 2022 revenue guidance to a range of $41.5 million to $45.5 million, compared to the prior 2022 guidance range of $40 million to $44 million.
Key Points:
- Revised 2022 revenue guidance to a range of $41.5 million to $45.5 million, compared to the prior 2022 guidance range of $40 million to $44 million.
- In the first quarter of 2022, total revenue was $8.9 million, an increase of 157% compared to the first quarter of 2021.
- Total operating expenses for the first quarter of 2022 were $20.3 million, a 66% increase from $12.3 million in the first quarter of 2021.
- On Thursday, May 5, 2022, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its first quarter 2022 financial results.
NASDAQ,
Interest,
Visual acuity,
GLOBE,
Patient,
Conference,
Technology,
Bank,
LAL,
IOL,
Health insurance ALISO VIEJO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference.
Key Points:
- ALISO VIEJO, Calif., April 22, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced plans to participate in the upcoming Bank of America Healthcare Conference.
- RxSights management is scheduled to present Tuesday, May 10, 2022, at 12:00pm PT / 3:00pm ET.
- Interested parties may access a live and archived webcast of the presentation on the Investors section of the companys website at: https://investors.rxsight.com/ .
- RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery.
NASDAQ,
International,
Visual acuity,
News,
GLOBE,
Patient,
Technology,
LAL,
IOL,
Investor,
Pharmaceutical industry ALISO VIEJO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) April 21, 2022 RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the first quarter 2022 after the market close on Thursday, May 5, 2022.
Key Points:
- ALISO VIEJO, Calif., April 21, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) April 21, 2022 RxSight, Inc., an ophthalmic medical device company dedicated to improving the vision of patients following cataract surgery, today announced that it will report financial results for the first quarter 2022 after the market close on Thursday, May 5, 2022.
- The companys management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
- RxSight, Inc. is a commercial-stage medical technology company dedicated to improving the vision of patients following cataract surgery.
- The LAL now features ActivShield technology, a revolutionary UV protection layer built into the lens.
LDD,
Society,
Biometrics,
ASCRS,
Poster,
Intraocular lens,
NASDAQ,
Visual acuity,
Ultraviolet,
GLOBE,
Semipermeable membrane,
Terminology,
Surgeon,
Technology,
Case series,
American Society of Cataract and Refractive Surgery,
Cataract,
EDT,
LAL,
Refractive surgery,
IOL,
Radial keratotomy,
Level 1,
Telescopic sight,
Medical device,
Risk management,
Patient,
MD Descemet Membrane Endothelial Keratoplasty Combined with Implantation of Light Adjustable Lens.
Key Points:
- Descemet Membrane Endothelial Keratoplasty Combined with Implantation of Light Adjustable Lens.
- Intraocular Lens Position of Light Adjustable Lens and Biometric Changes: 1-Year Follow-up.
- Light Adjustable Intraocular Lens in Patients with Radial Keratotomy Undergoing Cataract Surgery: A Case Series.
- The RxSight Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens (LAL), RxSight Light Delivery Device (LDD) and accessories, is the first and only commercially available intraocular lens (IOL) technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
